Immunome (IMMU +2.4%) inks an agreement with South Korea-based pH Pharma Co., Ltd. aimed at the discovery of novel antibody-drug conjugates (ADCs) for cancer.
Under the terms of the partnership, Immunome will
be responsible for initial antibody discovery and prioritization work
with its proprietary platform while pH Pharma will conjugate the
antibody candidates to its proprietary ADC payloads and test the ADC
candidates for safety and efficacy.
PH Pharma will have the right to develop and
commercialize the first candidate. The rights to subsequent candidates
will be determined via a selection process. The rightholder will pay the
other party up to $100M in milestones per product plus royalties. The
companies will share revenues from sublicensing deals.
https://seekingalpha.com/news/3507298-immunome-teams-ph-pharma-cancer-shares-2-percent
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.